Xilio Therapeutics (NASDAQ:XLO) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Xilio Therapeutics (NASDAQ:XLO) announced its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08), FiscalAI reports. Xilio Therapeutics had a negative net margin of 374.79% and a negative return on equity of 399.15%. The firm had revenue of $19.07 million during the quarter, compared to analysts’ expectations of $18.64 million.

Xilio Therapeutics Price Performance

XLO traded down $0.08 during trading hours on Thursday, reaching $0.69. The company’s stock had a trading volume of 1,139,943 shares, compared to its average volume of 1,727,046. The stock has a market cap of $35.81 million, a PE ratio of -0.91 and a beta of -0.08. Xilio Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.70. The business’s 50-day moving average is $0.78 and its 200-day moving average is $0.75.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Wall Street Zen cut shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 16th. Leerink Partnrs raised shares of Xilio Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Xilio Therapeutics in a research note on Wednesday, October 8th. Finally, Leerink Partners started coverage on Xilio Therapeutics in a research report on Wednesday, August 6th. They issued an “outperform” rating and a $2.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Xilio Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $2.00.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.